Try our beta test site

Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia

This study has been terminated.
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Clare Twist, Stanford University Identifier:
First received: April 7, 2006
Last updated: June 1, 2016
Last verified: November 2012
This is a phase I trial in patients with relapsed or refractory leukemia of a human monoclonal antibody that kills B cell acute lymphoblastic leukemia. The trial will study the safety, pharmacokinetics, and anti-tumor activity of the antibody given as a single agent and with vincristine.

Condition Intervention Phase
Leukemia, Lymphocytic, Acute
Acute Lymphoid Leukemia (ALL)
Drug: Human mAb 216
Drug: Vincristine
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Study of mAb 216 With Chemotherapy for the Treatment of Pediatric Patients With Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Maximum tolerable dose without toxicity [ Time Frame: not known ]
  • Safety

Secondary Outcome Measures:
  • Decrease in leukemic blasts

Enrollment: 4
Study Start Date: September 2004
Study Completion Date: July 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Human mAb 216 Drug: Human mAb 216
Two treatment courses of mAb infusion will be given, with the same dose of antibody administered on Day 0 and on Day 7.
Drug: Vincristine
Vincristine 1.5 mg/m2/dose (max dose = 2 mg) IVP on weekly x 4 doses (Days 7, 14, 21, 28)


Ages Eligible for Study:   12 Months to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:- Patients must be > than 12 months at the time of study entry.

  • Patients must have had histologic verification of B-lineage ALL with bone marrow relapse or refractory disease that is unresponsive to traditional chemotherapy.
  • For patients WITHOUT prior allogeneic bone marrow transplant (BMT):

    • Second or subsequent bone marrow relapse
    • Primary refractory marrow disease
    • M3 marrow (> 25% blasts)
  • For patients WITH prior allogeneic BMT:

    • First or subsequent bone marrow relapse post-BMT
    • M3 marrow or M2 (> 5% and < 25% blasts) if cytogenetic or variable number tandem repeat (VNTR) confirmation
  • Confirmation of antibody reactivity
  • Patient's leukemic blasts (peripheral blood or marrow) must be documented to bind mAb 216 in vitro (Teng lab).
  • Patient's red blood cell (RBC) documented to NOT express fetal "i" antigen and RBC shown to NOT bind mAb 216 in vitro (Teng lab)
  • Patient must not be eligible for therapies of higher priority
  • Performance level Karnofsky 50% for patients > 10 years of age and Lansky >= 50 for patients <= 10 years of age.
  • Life expectancy must be at least 8 weeks.
  • Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study:

    • Myelosuppressive chemotherapy: must not have been received within 2 weeks of entry onto this study.
    • Biologic: at least 7 days since the completion of therapy with a biologic agent.
  • No hematologic criteria for white blood cell (WBC), hemoglobin (Hgb), or platelets
  • Patients with thrombocytopenia should be responsive to platelet transfusions and must not have uncontrolled bleeding.
  • Adequate renal function defined as: a serum creatinine that is less than or equal to 1.5 x normal for age
  • Adequate liver function defined as: total bilirubin <= 1.5 x upper limit of normal (ULN) for age, and SGPT (ALT) <= 5 x upper limit of normal (ULN) for age
  • Adequate cardiac function defined as: shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide study.
  • All patients and/or their parents or legal guardians must sign a written informed consent/assent.
  • All Institutional Review Board (IRB) and Food and Drug Administration (FDA) requirements for human studies must be met.

Exclusion Criteria:- Central nervous system (CNS) 3 or refractory CNS leukemia

  • Isolated extramedullary relapse
  • Uncontrolled infection
  • Lack of mAb 216 binding to patient's leukemic blasts in vitro
  • Binding of mAb 216 to the"i" antigen on patient's erythrocytes
  • Prior treatment with rituximab
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00313053

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Clare Twist
National Institutes of Health (NIH)
Principal Investigator: Clare J. Twist M.D. Stanford University
  More Information

Responsible Party: Clare Twist, Associate Professor of Pediatrics, Stanford University Identifier: NCT00313053     History of Changes
Other Study ID Numbers: PEDSMAB216
13822 ( Other Identifier: Stanford IRB )
Study First Received: April 7, 2006
Last Updated: June 1, 2016

Additional relevant MeSH terms:
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on March 30, 2017